DK1002792T3 - 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse - Google Patents

2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse

Info

Publication number
DK1002792T3
DK1002792T3 DK98911211T DK98911211T DK1002792T3 DK 1002792 T3 DK1002792 T3 DK 1002792T3 DK 98911211 T DK98911211 T DK 98911211T DK 98911211 T DK98911211 T DK 98911211T DK 1002792 T3 DK1002792 T3 DK 1002792T3
Authority
DK
Denmark
Prior art keywords
compound
aminopropane
intermediates
synthesis
drug
Prior art date
Application number
DK98911211T
Other languages
Danish (da)
English (en)
Inventor
Kunitomo Adachi
Tokushi Hanano
Yukio Hoshino
Tetsuro Fujita
Yoshiyuki Aoki
Koji Teshima
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Application granted granted Critical
Publication of DK1002792T3 publication Critical patent/DK1002792T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/16Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same carbon atom of an acyclic carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/34Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton and at least one hydroxy group bound to another carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C223/00Compounds containing amino and —CHO groups bound to the same carbon skeleton
    • C07C223/02Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98911211T 1997-04-04 1998-04-03 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse DK1002792T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8625597 1997-04-04
PCT/JP1998/001571 WO1998045249A1 (fr) 1997-04-04 1998-04-03 Composes 2-aminopropane-1,3-diol, leur utilisation pharmaceutique, et intermediaires servant a leur synthese
EP98911211A EP1002792B1 (fr) 1997-04-04 1998-04-03 Composes 2-aminopropane-1,3-diol, leur utilisation pharmaceutique, et intermediaires servant a leur synthese

Publications (1)

Publication Number Publication Date
DK1002792T3 true DK1002792T3 (da) 2004-11-22

Family

ID=13881722

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98911211T DK1002792T3 (da) 1997-04-04 1998-04-03 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse
DK03003623T DK1319651T3 (da) 1997-04-04 1998-04-03 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03003623T DK1319651T3 (da) 1997-04-04 1998-04-03 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse

Country Status (18)

Country Link
US (2) USRE39072E1 (fr)
EP (2) EP1002792B1 (fr)
JP (1) JP4045364B2 (fr)
KR (1) KR100551931B1 (fr)
CN (2) CN1290819C (fr)
AT (2) ATE271028T1 (fr)
AU (1) AU735853B2 (fr)
BR (1) BR9808481A (fr)
CA (1) CA2286315C (fr)
DE (2) DE69830756T2 (fr)
DK (2) DK1002792T3 (fr)
ES (2) ES2226110T3 (fr)
IL (3) IL155065A (fr)
NZ (1) NZ500713A (fr)
PT (2) PT1319651E (fr)
RU (1) RU2198162C2 (fr)
SI (2) SI1002792T1 (fr)
WO (1) WO1998045249A1 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861442B1 (en) * 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2002006268A1 (fr) 2000-07-13 2002-01-24 Sankyo Company, Limited Derives d'alcool amino
AU2001296536A1 (en) 2000-10-03 2002-04-15 University Of Virginian Patent Foundation Novel lysophosphatidic acid receptor agonists and antagonists
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
DE60234092D1 (de) 2001-01-30 2009-12-03 Univ Virginia Agonisten und antagonisten von sphingosin-1-phosphatrezeptoren
CA2435739A1 (fr) * 2001-02-22 2002-09-06 Novartis Ag Utilisation d'agents de homing lymphocytaire accelere pour la production d'un medicament destine au traitement de la reprise fonctionnelle retardee du greffon
US20030072717A1 (en) * 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
WO2002076995A2 (fr) * 2001-03-26 2002-10-03 Novartis Ag Derives de 2-amino-propanol
CN1236831C (zh) * 2001-05-21 2006-01-18 茵捷特数码浮质有限公司 用于经肺部途径递送蛋白质的组合物
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
DE60235900D1 (de) * 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
CN1329372C (zh) * 2001-09-27 2007-08-01 杏林制药株式会社 二芳基硫醚衍生物及其加成盐和免疫抑制剂
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
KR100836547B1 (ko) 2002-01-11 2008-06-10 상꾜 가부시키가이샤 아미노 알코올 유도체 또는 포스폰산 유도체 및 이들을함유하는 의약 조성물
US6797722B2 (en) * 2002-05-03 2004-09-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
CA2483594C (fr) 2002-05-16 2011-02-15 Novartis Ag Utilisation d'agents de liaison du recepteur edg dans le cancer
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
CN100516024C (zh) 2002-09-13 2009-07-22 诺瓦提斯公司 氨基-丙醇衍生物
PL375053A1 (en) * 2002-09-24 2005-11-14 Novartis Ag Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
EP2316431B1 (fr) * 2003-04-08 2015-09-30 Novartis AG Composition orale solide comprenant un agoniste de récepteur S1P et alcool de sucre
AU2008200368B2 (en) * 2003-04-08 2011-04-28 Mitsubishi Tanabe Pharma Corporation Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
AU2011205050B2 (en) * 2003-04-08 2014-01-30 Mitsubishi Tanabe Pharma Corporation Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
CN1777575B (zh) * 2003-04-30 2010-05-12 诺瓦提斯公司 作为1-磷酸-鞘氨醇受体调节剂的氨基-丙醇衍生物
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
EP1484057A1 (fr) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Utilization des derives de 2-amino-1,3-propanediol pour la preparation d'un medicament destine au traitement des certains douleurs
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0324210D0 (en) 2003-10-15 2003-11-19 Novartis Ag Organic compounds
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
WO2005079788A1 (fr) 2004-02-24 2005-09-01 Sankyo Company, Limited Composé d’alcool aminé
AU2005237254B2 (en) * 2004-05-03 2010-02-04 Novartis Ag Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
EP1750722A4 (fr) 2004-05-06 2010-03-10 Univ Virginia Nouveaux antagonistes selectifs du recepteur de l'acide lysophosphatidique
GB0411929D0 (en) * 2004-05-27 2004-06-30 Novartis Ag Organic compounds
WO2006115509A2 (fr) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
PL1772145T3 (pl) * 2004-07-16 2011-08-31 Kyorin Seiyaku Kk Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym
JP4919374B2 (ja) * 2004-07-29 2012-04-18 第一三共株式会社 免疫抑制剤としての医薬組成物
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
PL1773307T3 (pl) 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
US20060223866A1 (en) * 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
RU2007109207A (ru) * 2004-08-13 2008-09-20 Прикис Фамэсьютикэлс, Инк. (US) Соединения-модуляторы активности рецептора сфингозин-1-фосфата (варианты), фармацевтическая композиция, содержащая указанные соединения, и способ лечения нарушения, ассоциированного со сфингозин-1-фосфатом
PT2511262T (pt) * 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
WO2006058316A1 (fr) 2004-11-29 2006-06-01 Novartis Ag Posologie d'un agoniste du recepteur s1p
KR20070102538A (ko) * 2005-02-08 2007-10-18 노파르티스 아게 S1p 수용체 효능제/조절제와 면역억제성 약물의 조합에의한 항림프구 항체 유도
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
TW200702326A (en) * 2005-05-31 2007-01-16 Mitsubishi Pharma Corp 2-aminobutanol compound and its pharmaceutical use
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ppar調節劑之醫藥組成物的用途
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
PT1932522E (pt) * 2005-10-07 2012-06-26 Kyorin Seiyaku Kk Agente terapêutico para doenças do fígado contendo, como princípio activo, um derivado de 2- amino-1,3-propanodiol
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2643680A1 (fr) 2006-04-11 2007-11-22 Novartis Ag Composes organiques et leurs utilisations
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
TW200815600A (en) 2006-08-04 2008-04-01 Daiichi Sankyo Co Ltd An enzyme for phosphorizing a medicine
NZ574012A (en) * 2006-08-08 2012-02-24 Kyorin Seiyaku Kk Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
CN101501049B (zh) * 2006-08-08 2013-04-24 杏林制药株式会社 氨基磷酸酯衍生物以及将它们作为有效成分的s1p受体调节剂
PL3103448T3 (pl) 2006-09-26 2019-12-31 Novartis Ag Kompozycje farmaceutyczne zawierające modulator S1P
US20080261986A1 (en) * 2007-03-30 2008-10-23 Friden Phillip M Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug
EP2168944B1 (fr) 2007-06-14 2016-05-11 Mitsubishi Tanabe Pharma Corporation Composé aminé et son utilisation pharmaceutique
DE102007039954A1 (de) * 2007-08-23 2009-02-26 Henkel Ag & Co. Kgaa Reduktive Entfärbung keratinhaltiger Fasern
PT2952177T (pt) 2007-10-12 2021-04-26 Novartis Ag Composições compreendendo moduladores do recetor de fosfato de esfingosina 1 (s1p)
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
ES2665336T3 (es) 2012-04-23 2018-04-25 Mitsubishi Tanabe Pharma Corporation Compuesto amina y su uso para propósitos médicos
CN110862409B (zh) * 2019-12-04 2021-08-20 江南大学 一种制备含二元醇结构的硅烷类化合物及其改性水性聚氨酯的方法
US20220153684A1 (en) * 2020-11-13 2022-05-19 Shivalik Rasayan Limited Process for preparation of fingolimod hydrochloride

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660488A (en) * 1965-07-16 1972-05-02 Phillips Petroleum Co 2-halo-alkylene- and -cyclopentylene-2-amino-propane 1 3-diols
ATE172711T1 (de) * 1992-10-21 1998-11-15 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
KR100358922B1 (ko) 1994-08-22 2003-01-24 미쯔비시 웰 파마 가부시키가이샤 벤젠화합물및그의의약으로서의용도

Also Published As

Publication number Publication date
ATE298740T1 (de) 2005-07-15
EP1319651A2 (fr) 2003-06-18
PT1319651E (pt) 2005-09-30
KR20010006004A (ko) 2001-01-15
EP1002792B1 (fr) 2004-07-14
KR100551931B1 (ko) 2006-02-16
EP1002792A4 (fr) 2002-03-20
CN1480450A (zh) 2004-03-10
AU6523098A (en) 1998-10-30
SI1319651T1 (en) 2005-10-31
IL155066A (en) 2004-06-20
EP1002792A1 (fr) 2000-05-24
AU735853B2 (en) 2001-07-19
EP1319651A3 (fr) 2004-01-02
RU2198162C2 (ru) 2003-02-10
CA2286315A1 (fr) 1998-10-15
CA2286315C (fr) 2007-03-06
DK1319651T3 (da) 2005-08-01
NZ500713A (en) 2000-07-28
DE69830756T2 (de) 2006-05-04
ES2226110T3 (es) 2005-03-16
EP1319651B1 (fr) 2005-06-29
SI1002792T1 (en) 2004-12-31
ATE271028T1 (de) 2004-07-15
CN1137086C (zh) 2004-02-04
CN1290819C (zh) 2006-12-20
BR9808481A (pt) 2000-05-23
IL132208A (en) 2003-07-31
IL155066A0 (en) 2003-10-31
PT1002792E (pt) 2004-12-31
ES2240868T3 (es) 2005-10-16
IL155065A (en) 2004-01-04
CN1259117A (zh) 2000-07-05
WO1998045249A1 (fr) 1998-10-15
DE69825056D1 (de) 2004-08-19
USRE39072E1 (en) 2006-04-18
DE69830756D1 (de) 2005-08-04
US6214873B1 (en) 2001-04-10
IL132208A0 (en) 2001-03-19
JP4045364B2 (ja) 2008-02-13
IL155065A0 (en) 2003-10-31
DE69825056T2 (de) 2005-08-25

Similar Documents

Publication Publication Date Title
DK1002792T3 (da) 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse
ID27285A (id) Turunan benzamida untuk pengobatan penyakit yang diperantarai oleh sitokina
EP1126836A4 (fr) Inhibiteurs benzamidiques de canaux potassiques
BR0008173A (pt) Composto de amida e seu uso como campo técnico de medicina da invenção
DE69321823D1 (de) 2-amino-1, 3- propandiolverbindung und immunosuppressium
PT1063228E (pt) Derivados de cicloalcenos processo para a sua preparacao e utilizacao
BR9407711A (pt) Composto de ciclopeptídeo processo para preparaçao de um composto de ciclopeptídeo e parasiticida
ES2148254T3 (es) Peptidos antimicrobianos ciclicos y preparacion de los mismos.
HUT62296A (en) Herbicidal composition comprising hydantoin derivative as active ingredient and process for producing the active ingredient
ES2096073T3 (es) Derivado de benzamida.
DE68926981D1 (de) Cephemverbindungen und Verfahren zu ihrer Herstellung
HK1061674A1 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
DK0947513T3 (da) Tricykliske aminderivater
ATE86117T1 (de) Zusammensetzung gegen leberkrankheiten.
ATE79752T1 (de) Verwendung von chromanderivaten zur herstellung eines medikamentes zur behandlung von depressiven zustaenden.
TH38253A (th) อนุพันธ์ 6,6-เฮเทอโร-ไบไซคลิคที่ถูกเข้าแทนที่